Patents Examined by Vanessa L. Ford
  • Patent number: 10149890
    Abstract: The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and r
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: December 11, 2018
    Assignee: “SCIENTIFIC CENTER OF ANTI-INFECTIOUS DRUGS” JOINT-STOCK COMPANY
    Inventors: Alexandr Ivanovich Ilin, Murat Esengalievich Kulmanov
  • Patent number: 10143776
    Abstract: Slow vascularization of functional blood limits the transplantation of tissue constructs and the recovery of ischemic and wounded tissues. Blood vessel ingrowth into polysaccharide-based hydrogel scaffolds remains a challenge. A synergistic effect of multiple angiogenic GFs was established; the co-encapsulation of VEGF plus other growth factors induced more and larger blood vessels than any individual GF, while the combination of all GFs dramatically increased the size and number of newly formed functional vessels. Rapid, efficient, and functional neovascularization may be achieved.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: December 4, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Sharon Gerecht, Guoming Sun, Yu-I Shen
  • Patent number: 10137236
    Abstract: A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: November 27, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Yoram Vodovotz, Alexey Solovyev, David Okonkwo, Maxim Mikheev, Qi Mi, Jorg Gerlach, Gregory M Constantine
  • Patent number: 10117919
    Abstract: This document provides methods and materials for generating CD8? T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide. For example, methods and materials for using a polypeptide consisting of an SLAFLPESFD amino acid sequence in vivo or in vitro to generate CD8+ T cells having the ability to recognize and lyse cancer cells expressing a HER2/neu polypeptide are provided.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: November 6, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Keith L. Knutson, Andrea M. Henle
  • Patent number: 10106601
    Abstract: The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 23, 2018
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventors: Peter Carmeliet, Sonja Loges
  • Patent number: 10093712
    Abstract: The present invention provides novel immune-stimulatory polypeptides, and methods for their use and identification.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: October 9, 2018
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, Valerie Jacobs, Kenneth Hoober
  • Patent number: 10053695
    Abstract: The invention provides compositions and methods for targeting CCR10 and/or the CCR10/ligand axis to modulate the immune response in a subject.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: August 21, 2018
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Na Xiong, Mingcan Xia
  • Patent number: 10047156
    Abstract: The invention provides an isolated antibody or a fragment thereof, which is directed to the human chemokines CXCL1, CXCL7 and CXCL8, said antibody or fragment being capable of binding to the human chemokine CXCL1 with an equilibrium dissociation constant (KD) of at most 16 nM, to the human chemokine CXCL7 with an equilibrium dissociation constant (KD) of at most 5 nM and to the human chemokine CXCL8 with an equilibrium dissociation constant (KD) of at most 45 nM, as determined by surface plasmon resonance. The invention also provides some applications of said isolated antibody.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: August 14, 2018
    Assignees: Centre National De La Recherche Scientifique (CNRS), Universite de Nice Sophia Antipolis
    Inventors: Gilles Pages, Renaud Grepin
  • Patent number: 10040856
    Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anto-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 7, 2018
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Nelson Ruiz-Opazo, Victoria L. M. Herrera
  • Patent number: 10015980
    Abstract: A method includes a step of identifying a subject in need of diet modification; and administering a first diet to the subject for a first time period. The first diet provides 4.5 to 7 kilocalories per pound of subject for a first day and 3 to 5 kilocalories per pound of subject per day for a second to fifth day of the first diet. The first diet includes less than 30 g of sugar on the first day; less than 20 g of sugar on the second to fifth days; less than 28 g of proteins on the first day; less than 18 g of proteins on days the second to fifth days; 20 to 30 grams of monounsaturated fats on the first day; 10 to 15 grams of monounsaturated fats on the second to fifth days; and between 6 and 10 grams of polyunsaturated fats on the first day.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: July 10, 2018
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Valter D. Longo, Chia-Wei Cheng, Sebastian Brandhorst, Min Wei
  • Patent number: 10012654
    Abstract: The present invention provides a method of determining whether a patient with inflammatory bowel disease (IBD) and who has been treated with anti TNF? therapy is in immunological remission (IR), said method comprising determining the level of a cytokine selected from TNF?, IL-17 and IFN-y in a Gl mucosal sample from said patient. Also provided are methods of prognosis and treatment using said method of determination, in particular discontinuing treatment if said patient is in IR and continuing treatment if said patient is not in IR.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: July 3, 2018
    Assignee: UNIVERSITY OF TROMSØ
    Inventors: Jon Florholmen, Trine Olsen, Renathe Rismo, Rasmus Goll, Guanglin Cui
  • Patent number: 9993565
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: June 12, 2018
    Assignee: NEOVACS
    Inventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
  • Patent number: 9994612
    Abstract: Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Shelly Pizarro, Ailen Sanchez, Charles H. Schmelzer
  • Patent number: 9980987
    Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: May 29, 2018
    Assignee: Noveome Biotherapeutics, Inc.
    Inventors: Larry R Brown, Richard A Banas, Howard C Wessel, Elise M Gill
  • Patent number: 9977029
    Abstract: Sarcoidosis is a multisystem disease characterized by granulomatous inflammation in affected organs. The present invention discloses kits and a system for a blood test using mycobacterial catalase-peroxidase that has a high positive predictive value for confirming a diagnosis of sarcoidosis.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 22, 2018
    Inventor: David R. Moller
  • Patent number: 9964542
    Abstract: Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of bladder cancer in a subject are provided by detecting in a urine sample a combination of biomarkers. In one embodiment of the invention, biomarker panels consisting of individual targets listed in Tables 4 through 10 may be detected. In another embodiment of the invention, multiplex biomarker panels of various composition, but including those biomarkers listed above may be detected.
    Type: Grant
    Filed: January 31, 2016
    Date of Patent: May 8, 2018
    Inventors: Steven Goodison, Charles J. Rosser
  • Patent number: 9963701
    Abstract: The present invention relates to a pharmaceutical composition for treating a radiation- or drug-resistant cancer, containing an agent capable of inhibiting the expression of hepatoma-derived growth factor (HDGF)-related protein-3 (HRP-3), a method of treating a radiation- or drug-resistant cancer by administering the pharmaceutical composition, and the use of an HRP-3 inhibitor for preparing an agent for treating a radiation- or drug-resistant cancer. The use of the pharmaceutical composition of the present invention enables to treat a resistant cancer in combination with a conventional anticancer chemotherapy or radiotherapy. Accordingly, the pharmaceutical composition of the present invention can reduce both the costs for developing anticancer agents against resistant cancers and the costs for treating cancers in patients, thus being useful for the economic and effective treatment of resistant cancers.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: May 8, 2018
    Assignee: KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES
    Inventors: Sang Gu Hwang, Hong Shik Yun
  • Patent number: 9956274
    Abstract: The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: May 1, 2018
    Assignee: UCB Biopharma SPRL
    Inventor: Terence Seward Baker
  • Patent number: 9951111
    Abstract: The subject invention pertains to agonist peptides of type I interferons and methods of using the peptides. These peptides are based on the amino acid sequence of the C-terminus region of the type I IFN molecules and are capable of binding to the cytoplasmic domain of type I IFN receptors. Surprisingly, these peptides were found to possess the same or similar biological activity as that associated with the full-length, mature type I IFN proteins, even though these peptides do not bind to the extracellular domain of the type I IFN receptors. In one embodiment, the peptide is a peptide of IFN?. In another embodiment, the peptide is a peptide of IFN?. Exemplified peptides of the invention include those having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40. The subject peptides have been shown to effect increased resistance to viral infection.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: April 24, 2018
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Howard M. Johnson, Chulbul M. Ahmed
  • Patent number: 9950035
    Abstract: Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII, Compositions may also contain white blood cells and platelets.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 24, 2018
    Assignee: Biomet Biologics, LLC
    Inventors: Jeffrey R. Binder, Joel C. Higgins, Michael D. Leach, Krista O'Shaughnessey, Jennifer E. Woodell-May